Pediatric Blood and Marrow Transplantation & Cellular Therapy
Angela Panoskaltsis-Mortari, PhD, Professor, Division of Pediatric Blood and Marrow Transplantation & Cellular Therapy
The Blood and Marrow Transplantation & Cellular Therapy Program is dedicated to innovative and exceptional patient care, research and education.
The University of Minnesota is an internationally respected pioneer in the area of Blood and Marrow Transplantation & Cellular Therapy (BMT&CT). The first successful human allogenic bone marrow transplant was performed at the University of Minnesota in 1968. Other “firsts” include the first transplant to treat a patient with lymphoma (1975), the first transplant to treat an inherited metabolic disease (1982), and the world’s first umbilical cord blood transplant performed using pre-implantation genetic testing to ensure a perfect tissue match (2000). Our clinical program is recognized as the second largest unrelated donor transplant program in the country and one of the largest umbilical cord blood transplant centers in the world.
Education & Training
Our division offers a one-year non-accredited fellowship in Pediatric BMT&CT. We also collaborate with the three-year ACGME-accredited Pediatric Hematology-Oncology Fellowship Program at U of M.
Patient Care
For over 50 years, we have demonstrated excellent, expert, and innovative care of our blood and marrow transplant patients. Families come from across the world to receive care from our team.
Contact Us
Appointments: (612) 365‑8100
Provider Referrals: (612) 273-2800
Administrative Office
Phone: (612) 626-2961
Fax: (612) 626-4074
Mailing Address
Mayo Mail Code 366
420 Delaware Street SE
Minneapolis, MN 55455
Shipping Address
425 East River Road
Suite 660
Attn: Pediatric BMT & CT
Minneapolis, MN 55455
Note: Before shipping, contact the administrative office to assure that your package is addressed to the correct location
Research
Our researchers continue to break new ground in the areas of alternative stem cell therapies, cord blood transplantation, genetic engineering to reduce the side effects of BMT&CT, genetic engineering to potentially treat disease, and immune-based therapies.